Nifeviroc is regarded as a catalyst to upgrade the effect of the cokctail.
Following the agreement with Avexa, Targetdrug will possess the rights for developing Nifeviroc in China. Avexa will take charge of post-research expenses, develop it in the international marketplace and share global benefits with Targetdrug.
looks good!
seek expert advice
- Forums
- ASX - By Stock
- AVX
- nifeviroc
nifeviroc
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)